OncoSec Medical Stock Price, News & Analysis (NASDAQ:ONCS)

$1.78 +0.01 (+0.56 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.78
Today's Range$1.76 - $1.83
52-Week Range$0.88 - $2.95
Volume655,359 shs
Average Volume989,538 shs
Market Capitalization$63.58 million
P/E Ratio-1.73
Dividend YieldN/A
Beta3.37

About OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical logoOncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ONCS
CUSIPN/A
Phone+1-858-2107333

Debt

Debt-to-Equity RatioN/A
Current Ratio4.01%
Quick Ratio4.01%

Price-To-Earnings

Trailing P/E Ratio-1.72815533980583
Forward P/E Ratio-2.62
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book3.63

Profitability

Trailing EPS($1.03)
Net Income$-21,440,000.00
Net MarginsN/A
Return on Equity-144.61%
Return on Assets-110.75%

Miscellaneous

Employees35
Outstanding Shares42,940,000

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) posted its earnings results on Wednesday, October, 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.05. View OncoSec Medical's Earnings History.

When will OncoSec Medical make its next earnings announcement?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for OncoSec Medical.

Where is OncoSec Medical's stock going? Where will OncoSec Medical's stock price be in 2018?

5 brokerages have issued 12-month price objectives for OncoSec Medical's shares. Their predictions range from $4.00 to $6.00. On average, they anticipate OncoSec Medical's stock price to reach $5.00 in the next twelve months. View Analyst Ratings for OncoSec Medical.

What are Wall Street analysts saying about OncoSec Medical stock?

Here are some recent quotes from research analysts about OncoSec Medical stock:

  • 1. Maxim Group analysts commented, "Oncosec announced that the P2b study (PISCES/KEYNOTE-695) in late-stage melanoma evaluating TAVO (DNA-based IL-12, intratumoral) + Keytruda has dosed the first patient." (12/14/2017)
  • 2. HC Wainwright analysts commented, "We believe preliminary interim data—based on the first 16-20 patients—could be reported in late 2017 or early 2018. Management have indicated that an ORR of at least 30% would be considered a success for the PISCES study. We note that positive results from the interim analysis may allow the company to apply for Breakthrough Therapy designation in patients who have failed anti- PD-1 monotherapies. In addition, OncoSec may report 24-month follow- up data from the Phase 2 investigator-sponsored trial later this year. In the wake of this update, we reiterate our Buy rating and $6 price target. 43% ORR in Phase 2 combo trial. A prior investigator-sponsored Phase 2 combo study of ImmunoPulse IL-12 and Keytruda in 22 metastatic melanoma patients reported positive data. These patients were predicted to have low likelihoods of response to anti-PD-1 monotherapies based on biomarker assays. The results showed a 43% (9/21) ORR at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. There were 24% (5/21) complete responders and 19% (4/22) partial responders. Of note, nine out of the 22 patients enrolled had prior checkpoint inhibitor therapy; ORR for this subset of patients was 33% (3/9). The data showed that intra-tumoral electroporation of interleukin-12 DNA, combined with pembrolizumab, can effectively alter the tumor microenvironment and increase tumor- specific CD8+ T-cells, which drive a systemic anti-tumor immune response. The combo therapy had an acceptable safety profile and was well tolerated." (6/2/2017)

Who are some of OncoSec Medical's key competitors?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:

  • Avtar S. Dhillon M.D., Independent Chairman of the Board (Age 56)
  • Punit S. Dhillon, President, Director (Age 36)
  • Daniel J. O'Connor Esq., Chief Executive Officer, Director
  • Richard B. Slansky, Chief Financial Officer (Age 59)
  • Sheela Mohan-Peterson J.D., Chief Legal and Compliance Officer (Age 54)
  • Sharron Gargosky PhD, Chief Clinical and Regulatory Officer (Age 52)
  • Gregory T. Mayes III, Director (Age 48)
  • James Michael DeMesa M.D., Independent Director (Age 59)
  • Anthony E. Maida III, Ph.D., Independent Director (Age 65)

Who owns OncoSec Medical stock?

OncoSec Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.39%), Deutsche Bank AG (0.37%), Sabby Management LLC (0.36%), J. Goldman & Co LP (0.23%) and MYDA Advisors LLC (0.21%). Company insiders that own OncoSec Medical stock include Daniel J O'connor and Punit Dhillon. View Institutional Ownership Trends for OncoSec Medical.

Who sold OncoSec Medical stock? Who is selling OncoSec Medical stock?

OncoSec Medical's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for OncoSec Medical.

Who bought OncoSec Medical stock? Who is buying OncoSec Medical stock?

OncoSec Medical's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, J. Goldman & Co LP and MYDA Advisors LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.

How do I buy OncoSec Medical stock?

Shares of OncoSec Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of OncoSec Medical stock can currently be purchased for approximately $1.78.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $63.58 million. The biotechnology company earns $-21,440,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. OncoSec Medical employs 35 workers across the globe.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 5820 Nancy Ridge Dr, SAN DIEGO, CA 92121-2842, United States. The biotechnology company can be reached via phone at +1-858-2107333 or via email at [email protected]


MarketBeat Community Rating for OncoSec Medical (ONCS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OncoSec Medical (NASDAQ:ONCS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.33$5.33$5.33
Price Target Upside: 204.88% upside152.76% upside166.67% upside359.77% upside

OncoSec Medical (NASDAQ:ONCS) Consensus Price Target History

Price Target History for OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical (NASDAQ:ONCS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$4.00LowView Rating Details
1/19/2018HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
12/14/2017Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
7/6/2017Dawson JamesReiterated RatingBuy$5.00HighView Rating Details
6/14/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
12/28/2016Ci CapitalInitiated CoverageBuyN/AView Rating Details
7/21/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

OncoSec Medical (NASDAQ:ONCS) Earnings History and Estimates Chart

Earnings by Quarter for OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical (NASDAQ ONCS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
10/25/2017Q4 2017($0.23)($0.28)ViewN/AView Earnings Details
6/1/2017Q3 2017($0.28)($0.22)ViewListenView Earnings Details
3/16/2017Q2 2017($0.31)($0.27)ViewN/AView Earnings Details
12/8/2016Q1 2017($0.36)($0.29)ViewN/AView Earnings Details
10/13/2016Q416($0.32)($0.39)ViewListenView Earnings Details
6/9/2016Q316($0.43)($0.37)ViewN/AView Earnings Details
3/8/2016Q216($0.46)($0.42)ViewN/AView Earnings Details
12/8/2015Q116($0.48)($0.47)ViewN/AView Earnings Details
10/14/2015Q415($0.40)($0.48)ViewListenView Earnings Details
6/9/2015Q3 2015($0.40)($1.15)ViewN/AView Earnings Details
3/12/2015($0.02)($0.02)ViewN/AView Earnings Details
12/8/2014($0.02)($0.02)ViewN/AView Earnings Details
10/13/2014($0.01)($0.01)ViewN/AView Earnings Details
6/16/2014($0.01)($0.02)ViewN/AView Earnings Details
6/14/2013Q3 2013($0.20)ViewN/AView Earnings Details
3/15/2013Q2 2013($0.40)($0.40)ViewN/AView Earnings Details
12/17/2012Q1 2013($0.40)($0.40)ViewN/AView Earnings Details
10/15/2012Q4 2012($0.40)($0.60)ViewN/AView Earnings Details
6/14/2012Q3 2012($0.40)($0.20)ViewN/AView Earnings Details
3/16/2012Q2 2012($0.40)($1.00)ViewN/AView Earnings Details
12/15/2011Q1 2012($0.40)$1.00ViewN/AView Earnings Details
10/20/2011Q4 2011($0.40)($1.00)ViewN/AView Earnings Details
6/14/2011Q3 2011($0.40)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

OncoSec Medical (NASDAQ:ONCS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS

Dividends

Dividend History for OncoSec Medical (NASDAQ:ONCS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

OncoSec Medical (NASDAQ ONCS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 4.87%
Insider Trades by Quarter for OncoSec Medical (NASDAQ:ONCS)
Institutional Ownership by Quarter for OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical (NASDAQ ONCS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Punit DhillonPresidentBuy3,000$0.88$2,640.00View SEC Filing  
2/5/2018Daniel J O'connorCEOBuy16,667$1.50$25,000.5016,667View SEC Filing  
7/31/2017Punit DhillonInsiderBuy3,000$0.88$2,640.00View SEC Filing  
1/31/2017Punit DhillonInsiderBuy3,000$0.99$2,970.00View SEC Filing  
10/16/2015Punit DhillonCEOBuy10,000$4.25$42,500.00100View SEC Filing  
6/10/2015Punit DhillonCEOBuy2,500$6.74$16,850.00View SEC Filing  
3/20/2014Anthony E Maida IIIDirectorBuy22,800$0.81$18,468.00View SEC Filing  
3/19/2014Punit DhillonCEOBuy50,000$0.80$40,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OncoSec Medical (NASDAQ ONCS) News Headlines

Source:
DateHeadline
OncoSec Medical Inc (ONCS) Expected to Post Earnings of -$0.19 Per ShareOncoSec Medical Inc (ONCS) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - February 17 at 7:14 PM
OncoSec Medical (ONCS) Coverage Initiated at Piper Jaffray CompaniesOncoSec Medical (ONCS) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - February 10 at 10:54 PM
OncoSec Medical Inc (ONCS) Receives Consensus Rating of "Buy" from BrokeragesOncoSec Medical Inc (ONCS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 9 at 10:12 AM
OncoSec Medical Inc (ONCS) CEO Acquires $25,000.50 in StockOncoSec Medical Inc (ONCS) CEO Acquires $25,000.50 in Stock
www.americanbankingnews.com - February 6 at 12:23 PM
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common StockOncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock
finance.yahoo.com - February 6 at 9:33 AM
OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common StockOncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock
finance.yahoo.com - February 1 at 9:40 AM
OncoSec Medical Incorporated Announces Proposed Public Offering of Common StockOncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 1 at 9:40 AM
 Brokerages Anticipate OncoSec Medical Inc (ONCS) Will Post Earnings of -$0.23 Per Share Brokerages Anticipate OncoSec Medical Inc (ONCS) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 31 at 9:10 PM
Avacta, OncoSec to Collaborate to Combine Avactas Affimer Protein Platform with OncoSecs Gene Delivery ... - BenzingaAvacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery ... - Benzinga
www.benzinga.com - January 22 at 8:06 AM
A Peek Into The Markets: US Stock Futures Drop After Government Shutdown - BenzingaA Peek Into The Markets: US Stock Futures Drop After Government Shutdown - Benzinga
www.benzinga.com - January 22 at 8:06 AM
Avacta, OncoSec to Collaborate to Combine Avactas Affimer Protein Platform with OncoSecs Gene Delivery Technology ImmunoPulseAvacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery Technology ImmunoPulse
finance.yahoo.com - January 22 at 8:06 AM
Avacta, OncoSec to Collaborate  to Combine Avactas Affimer Protein Platform with OncoSecs Gene Delivery Technology ImmunoPulseAvacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery Technology ImmunoPulse
feeds.benzinga.com - January 22 at 7:20 AM
OncoSec Medical (ONCS) PT Set at $6.00 by HC WainwrightOncoSec Medical (ONCS) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 1:58 PM
OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer StudyOncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study
finance.yahoo.com - January 18 at 11:14 AM
OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of DirectorsOncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors
finance.yahoo.com - January 16 at 10:17 AM
 Analysts Anticipate OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share Analysts Anticipate OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 14 at 11:06 PM
Oncosec Medical (ONCS) Provides 2018 Business Outlook - StreetInsider.comOncosec Medical (ONCS) Provides 2018 Business Outlook - StreetInsider.com
www.streetinsider.com - January 3 at 9:25 AM
OncoSec Provides 2018 Business OutlookOncoSec Provides 2018 Business Outlook
finance.yahoo.com - January 3 at 9:25 AM
OncoSec Medical (ONCS) vs. Nektar Therapeutics (NKTR) Critical SurveyOncoSec Medical (ONCS) vs. Nektar Therapeutics (NKTR) Critical Survey
www.americanbankingnews.com - December 29 at 11:50 AM
OncoSec Medical Inc (ONCS) Given Consensus Recommendation of "Buy" by AnalystsOncoSec Medical Inc (ONCS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 3:58 AM
OncoSec Medical (ONCS) Given a $6.00 Price Target by HC Wainwright AnalystsOncoSec Medical (ONCS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 15 at 12:04 PM
OncoSec Medical (ONCS) Stock Rating Reaffirmed by Maxim GroupOncoSec Medical (ONCS) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 14 at 12:34 PM
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with PembrolizumabOncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
finance.yahoo.com - December 14 at 10:25 AM
Zacks: Analysts Expect OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per ShareZacks: Analysts Expect OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - December 11 at 11:22 PM
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer - PR Newswire (press release)OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer - PR Newswire (press release)
www.prnewswire.com - December 5 at 11:59 AM
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific OfficerOncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
finance.yahoo.com - December 5 at 11:59 AM
OncoSec Medical (ONCS) Downgraded by ValuEngine to Strong SellOncoSec Medical (ONCS) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 2 at 10:36 PM
OncoSec Medical (ONCS) Scheduled to Post Quarterly Earnings on WednesdayOncoSec Medical (ONCS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 29 at 1:44 AM
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® PlatformOncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform
finance.yahoo.com - November 28 at 10:27 AM
OncoSec Medical Incorporated (ONCS) Given Average Rating of "Buy" by BrokeragesOncoSec Medical Incorporated (ONCS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 4:10 AM
Head to Head Contrast: OncoSec Medical (ONCS) & GenVec (GNVC)Head to Head Contrast: OncoSec Medical (ONCS) & GenVec (GNVC)
www.americanbankingnews.com - November 27 at 1:36 AM
OncoSec Medical Incorporated (ONCS) Expected to Announce Earnings of -$0.23 Per ShareOncoSec Medical Incorporated (ONCS) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 24 at 1:22 AM
Oncosec Medical (ONCS) Enters Warrant Exercise Agreement - StreetInsider.comOncosec Medical (ONCS) Enters Warrant Exercise Agreement - StreetInsider.com
www.streetinsider.com - November 15 at 7:06 AM
Oncosec Medical (ONCS) Reports $9.3M Warrant ExerciseOncosec Medical (ONCS) Reports $9.3M Warrant Exercise
www.streetinsider.com - November 14 at 6:30 AM
OncoSec Receives $9.3 Million Warrant ExerciseOncoSec Receives $9.3 Million Warrant Exercise
finance.yahoo.com - November 14 at 6:30 AM
Short Interest in OncoSec Medical Incorporated (ONCS) Increases By 203.3%Short Interest in OncoSec Medical Incorporated (ONCS) Increases By 203.3%
www.americanbankingnews.com - November 11 at 1:48 AM
Corporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with PembrolizumabCorporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with Pembrolizumab
finance.yahoo.com - November 10 at 2:58 PM
H.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 DataH.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 Data
finance.yahoo.com - November 10 at 2:58 PM
2 Stocks That Should Be on Your Radar Now2 Stocks That Should Be on Your Radar Now
finance.yahoo.com - November 9 at 3:19 PM
Oncosec Medical (ONCS) Announces Preclinical Data Show Multi-Gene Expression Platform for Delivery of Multiple ... - StreetInsider.comOncosec Medical (ONCS) Announces Preclinical Data Show Multi-Gene Expression Platform for Delivery of Multiple ... - StreetInsider.com
www.streetinsider.com - November 9 at 10:06 AM
OncoSec Appoints Daniel J. OConnor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial CompanyOncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company
finance.yahoo.com - November 9 at 10:06 AM
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma PatientsOncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients
finance.yahoo.com - November 9 at 10:06 AM
OncoSec Medical Inc (ONCS) Hits New Record Highs; Here’s WhyOncoSec Medical Inc (ONCS) Hits New Record Highs; Here’s Why
finance.yahoo.com - November 9 at 10:05 AM
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
finance.yahoo.com - November 9 at 10:05 AM
OncoSec Medical Incorporated (ONCS) Receives Buy Rating from HC WainwrightOncoSec Medical Incorporated (ONCS) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - November 9 at 7:58 AM
OnoSec Medical, FYE Financial Review, Analysts Target and Upcoming SITC PresentationOnoSec Medical, FYE Financial Review, Analysts Target and Upcoming SITC Presentation
finance.yahoo.com - November 7 at 8:15 AM
OncoSec Medical Incorporated (ONCS) Receives Consensus Recommendation of "Buy" from AnalystsOncoSec Medical Incorporated (ONCS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 3:50 AM
OncoSec Medicals (ONCS) CEO Punit Dhillon on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOncoSec Medical's (ONCS) CEO Punit Dhillon on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 27 at 9:07 AM
OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017
finance.yahoo.com - October 27 at 9:07 AM
OncoSec Medical (ONCS) and Its Competitors Head-To-Head ComparisonOncoSec Medical (ONCS) and Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - October 26 at 11:18 PM

SEC Filings

OncoSec Medical (NASDAQ:ONCS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OncoSec Medical (NASDAQ:ONCS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OncoSec Medical (NASDAQ ONCS) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.